SCDAA Statement About Gene Therapy Approval
On Dec. 8, 2023, the Food and Drug Administration (FDA) approved two cell-based gene therapies for sickle cell disease (SCD), Casgevy... Continue Reading
MARAC Statement: Health Insurance Coverage for MSD SCT
MARAC Statement: Health Insurance Coverage for Hematopoietic Stem Cell Transplant for Sickle Cell Disease from HLA-matched Sibling Donor (MSD HCT) Sept.... Continue Reading
MARAC Statement: Update About COVID
Sept. 16, 2023 – The worldwide pandemic of COVID-19 (SARS-CoV2) infections seem to have settled down, and we are now seeing... Continue Reading
MARAC Statement: Crizanlizumab (Adakveo)
July 7, 2023 – SCDAA’s Medical and Research Advisory Committee (MARAC) notes that the European Medicines Agency’s (EMA) Committee for Medicinal... Continue Reading
MARAC Statement: Penicillin Shortage
Penicillin VK solution is suffering from intermittent supply shortages. This can affect children with sickle cell disease. Penicillin VK in liquid... Continue Reading
MARAC Statement on Influenza
December 6, 2022 — The Sickle Cell Disease Association of America (SCDAA) Medical and Research Advisory Committee (MARAC) shares the following:... Continue Reading
MARAC Encourages Clinical Research Studies
The Sickle Cell Disease Association of America (SCDAA) Medical and Research Advisory Committee (MARAC) believes that progress in sickle cell disease... Continue Reading
MARAC Advisory Statement: Immunizations
August is National Immunization Awareness Month. What does that mean for individuals with sickle cell disease (SCD)? The Big Picture from... Continue Reading
MARAC Advisory Statement: Monkeypox
July 20 – The Sickle Cell Disease Association of America’s Medical and Research Advisory Committee (MARAC) is aware of the news... Continue Reading
MARAC Advisory: COVID-19 and Sickle Cell Disease
March 2022 – The Sickle Cell Disease Association of America’s Medical and Research Advisory Committee notes that news about COVID-19 continues... Continue Reading